Key players like Bayer AG and Fusion Pharmaceuticals are driving innovation in radioligand and alpha-particle therapies, addressing crucial market challenges such as radioisotope supply chain ...

The market is dominated by the APAC region, with significant growth in dietary supplements and bones & joint health ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €25.00. The ...